1. Home
  2. MURA vs KPLT Comparison

MURA vs KPLT Comparison

Compare MURA & KPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MURA
  • KPLT
  • Stock Information
  • Founded
  • MURA 2013
  • KPLT 2012
  • Country
  • MURA Ireland
  • KPLT United States
  • Employees
  • MURA N/A
  • KPLT N/A
  • Industry
  • MURA
  • KPLT Diversified Commercial Services
  • Sector
  • MURA
  • KPLT Consumer Discretionary
  • Exchange
  • MURA Nasdaq
  • KPLT Nasdaq
  • Market Cap
  • MURA 30.7M
  • KPLT 34.5M
  • IPO Year
  • MURA N/A
  • KPLT N/A
  • Fundamental
  • Price
  • MURA $1.82
  • KPLT $14.03
  • Analyst Decision
  • MURA Strong Buy
  • KPLT Hold
  • Analyst Count
  • MURA 3
  • KPLT 2
  • Target Price
  • MURA $12.00
  • KPLT $12.50
  • AVG Volume (30 Days)
  • MURA 281.7K
  • KPLT 28.3K
  • Earning Date
  • MURA 08-04-2025
  • KPLT 08-13-2025
  • Dividend Yield
  • MURA N/A
  • KPLT N/A
  • EPS Growth
  • MURA N/A
  • KPLT N/A
  • EPS
  • MURA N/A
  • KPLT N/A
  • Revenue
  • MURA N/A
  • KPLT $267,101,999.00
  • Revenue This Year
  • MURA N/A
  • KPLT $22.26
  • Revenue Next Year
  • MURA N/A
  • KPLT $11.03
  • P/E Ratio
  • MURA N/A
  • KPLT N/A
  • Revenue Growth
  • MURA N/A
  • KPLT 13.04
  • 52 Week Low
  • MURA $0.95
  • KPLT $5.08
  • 52 Week High
  • MURA $4.74
  • KPLT $15.47
  • Technical
  • Relative Strength Index (RSI)
  • MURA 36.95
  • KPLT 70.71
  • Support Level
  • MURA $1.53
  • KPLT $11.20
  • Resistance Level
  • MURA $1.83
  • KPLT $14.55
  • Average True Range (ATR)
  • MURA 0.17
  • KPLT 0.94
  • MACD
  • MURA -0.01
  • KPLT 0.01
  • Stochastic Oscillator
  • MURA 33.33
  • KPLT 84.35

About MURA Mural Oncology plc

Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.

About KPLT Katapult Holdings Inc.

Katapult Holdings Inc. is a technology-driven lease-to-own platform that integrates with omni-channel retailers and e-commerce platforms to power the purchase of everyday durable goods for underserved U.S. non-prime consumers. It is an e-commerce-focused FinTech company offering a lease-purchase solution to consumers and enabling essential transactions at the merchant point of sale. Katapult is associated with hundreds of retailers across the United States.

Share on Social Networks: